Clinical trials have complex eligibility criteria.Always talk to your clinician about you’re interest in participating in a trial.Learn why
HP Version - Clinical trials have complex eligibility criteria.Always talk to your clinician about you’re interest in participating in a trial.Learn why
Optimise reading forHealth ProfessionalsPatients
RecruitingLast updated: 31 January 2024
Clinical summaryEligibiltyParticipating hospitalsSupport
MAX-40279 is a dual inhibitor of FLT3 and FGFR. The aim of this trial is to develop this unique dual inhibitor to be more effective and in wider use for AML treatment than the current known FLT3 inhibitors. MAX-40279 will be provided as a capsule for oral use at 5mg, 25mg.
This trial is treating patients with Acute Myelogenous Leukaemia.
Use the hyperlinks, where available to access additional clinical trial information.
Maxinovel Pty., Ltd.
A Phase I Trial of MAX-40279 Given Orally to Subjects With Acute Myelogenous Leukemia (AML)
Blood / Lymphoma / Leukaemia
Share with email
Print this page
Acceptable liver function defined below:
Acceptable renal function defined below:
• Serum creatinine ≤ 1.5 times ULN or calculated creatinine clearance (by the Cockcroft-Gault formula) ≥ 60 mL/min
Acceptable coagulation status defined below:
Clinical trials have complex eligibility criteria.
Ask your doctor if this trial could be right for you.
+ Show non-recruiting hospitals
Tell us if you find this trial availability is not accurate.Report inaccuracy
Speak with someone who has cancer clinical trial experience.
If you need cancer information and practical support for yourself, a carer, family or friend, contact Cancer Council’s experienced cancer nurses on 131120.
When you are considering a cancer clinical trial, it is a good idea to discuss it with your family, friends or carers.
Thank you for helping us to increase accuracy of the trial. Our team will validate the information and update the information as soon as possible.